Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration

Acta Ophthalmologica

Volumn 89, Issue 4, 2011, Pages

  Nischler, Christian ^a   Oberkofler, Hannes ^a   Ortner, Christoph ^a   Paikl, Doris ^a   Riha, Wolfgang ^a   Lang, Nora ^a   Patsch, Wolfgang ^a   Egger, Stefan F ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

age related macular degeneration; anti VEGF; bevacizumab; complement factor H

Indexed keywords

BEVACIZUMAB; COMPLEMENT FACTOR H; HISTIDINE; TYROSINE;

AGED; ARTICLE; CLINICAL TRIAL; COMPLEMENT FACTOR H GENE; DISEASE SEVERITY; EXUDATIVE RETINA MACULA AGE RELATED DEGENERATION; FEMALE; GENOTYPE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; READING; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA LUTEA; SINGLE NUCLEOTIDE POLYMORPHISM; SUBRETINAL NEOVASCULARIZATION; THICKNESS; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ACUITY; VISUAL SYSTEM EXAMINATION;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; COMPLEMENT FACTOR H; FEMALE; FLUORESCEIN ANGIOGRAPHY; GENOTYPE; HUMANS; INTRAVITREAL INJECTIONS; MALE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 79958079300     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2010.02080.x     Document Type: Article

References (45)

1. Age-Related Eye Disease Study Research Group (2000): Risk factors associated with age-related macular degeneration: a case-control study in the Age-Related Eye Disease Study. Age-Related Eye Disease Study report number 3. Ophthalmology 107: 2224-2232.
2. Age-Related Eye Disease Study Research Group (2001): A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C & E, beta carotene, and zinc for age-related macular degeneration and vision loss. Arch Ophthalmol 119: 1417-1436.
3. Age-Related Eye Disease Study Research Group (2005): Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study. Age-Related Eye Disease Study report number 19. Ophthalmology 112: 533-539.
4. Blackmore TK, Fischetti VA, Sadlon TA, Ward HM, &, Gordon DL, (1998): M protein of the group A Streptococcus binds to the seventh short consensus repeat of human complement factor H. Infect Immun 66: 1427-1431. (Pubitemid 128471500)
5. Brantley MA Jr, Fang AM, King JM, Tewari A, Kymes SM, &, Shiels A, (2007a): Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 114: 2168-2173. (Pubitemid 350181136)
6. Brantley MA Jr, Edelstein SL, King JM, Apte RS, Kymes SM, &, Shiels A, (2007b): Clinical phenotypes associated with the complement factor H Y402H variant in age-related macular degeneration. Am J Ophthalmol 144: 404-408.
7. Brantley MA Jr, Edelstein SL, King JM, Plotzke MR, Apte RS, Kymes SM, &, Shiels A, (2008): Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy. Eye 23: 626-631.
8. Chowers I, Cohen Y, Goldenberg-Cohen N, et al., (2008): Association of complement factor H Y402H polymorphism with phenotype of neovascular age related macular degeneration in Israel. Mol Vis 14: 1829-1834.
9. Conley YP, Thalamuthu A, Jakobsdottir J, Weeks DE, Mah T, Ferrell RE, &, Gorin MB, (2005): Candidate gene analysis suggests a role for fatty acid biosynthesis and regulation of the complement system in the etiology of age-related maculopathy. Hum Mol Genet 14: 1991-2002. (Pubitemid 41418035)
10. Despriet DD, Klaver CC, Witteman JC, et al., (2006): Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. JAMA 296: 301-309. (Pubitemid 44079314)
11. Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, &, Farrer LA, (2005): Complement factor H polymorphism and age-related macular degeneration. Science 308: 421-424. (Pubitemid 40530082)
12. Eye Disease Case-Control Study Group (1992): Risk factors for neovascular age-related macular degeneration. Arch Ophthalmol 110: 1701-1708.
13. Feng X, Xiao J, Longville B, et al., (2009): Complement factor H Y402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration. Ophthalmology 116: 1908-1912.
14. Friedman DS, O'Colmain BJ, Munoz B, et al., (2004): Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122: 564-572. (Pubitemid 38456293)
15. Giannakis E, Jokiranta TS, Male DA, Ranganathan S, Ormsby RJ, Fischetti VA, Mold C, &, Gordon DL, (2003): A common site within factor H SCR 7 responsible for binding heparin, C-reactive protein and streptococcal M protein. Eur J Immunol 33: 962-969. (Pubitemid 36546684)
16. Goverdhan SV, Hannan S, Newsom RB, Luff AJ, Griffiths H, &, Lottery AJ, (2008): An analysis of the CFH Y402H genotype in AMD patients and controls from the UK, and response to PDT treatment. Eye 22: 849-854. (Pubitemid 351850525)
17. Haddad S, Chen CA, Santangelo SL, &, Seddon JM, (2006): The genetics of age-related macular degeneration: a review of progress to date. Surv Ophthalmol 51: 316-363. (Pubitemid 43970736)
18. Hageman GS, Anderson DH, Johnson LV, et al., (2005): A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci 102: 7227-7232. (Pubitemid 40696361)
19. Haines JL, Hauser MA, Schmidt S, et al., (2005): Complement factor H variant increases the risk of age-related macular degeneration. Science 308: 419-421. (Pubitemid 40530081)
20. Klaver CC, Wolfs RC, Assink JJ, van Duijn CM, Hofman A, &, de Jong PT, (1998): Genetic risk of age-related maculopathy: population-based familial aggregation study. Arch Ophthalmol 116: 1646-1651. (Pubitemid 29001964)
21. Klein RJ, Zeiss C, Chew EY, et al., (2005): Complement factor H polymorphism in age-related macular degeneration. Science 308: 385-389. (Pubitemid 40530070)
22. Lee AY, Raya AK, Kymes SM, Shiels A, &, Brantley MA, (2009): Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 93: 610-613.
23. Majewski J, Schultz DW, Weleber RG, et al., (2003): Age-related macular degeneration-a genome scan in extended families. Am J Hum Genet 73: 540-550. (Pubitemid 37076268)
24. Mullins RF, Russell SR, Anderson DH, &, Hageman GS, (2000): Drusen associated with aging and age-related macular degeneration contains proteins common to extracellular deposits assiciated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J 14: 835-846. (Pubitemid 30241660)
25. Radner W, Willinger U, Obermayer W, Mudrich C, Velikay-Parel M, &, Eisenwort B, (1998): A new reading chart for simultaneous determination of reading vision and reading speed. Klin Monatsbl Augenheilkd 213: 174-181. (Pubitemid 28460072)
26. Rivera A, Fisher SA, Fritsche LG, Keilhauer CN, Lichtner P, Meitinger T, &, Weber BH, (2005): Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet 14: 3227-3236. (Pubitemid 41631297)
27. Rodriguez de Cordoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, &, Sanchez-Corral P, (2004): The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol 41: 355-367. (Pubitemid 38639887)
28. Schick JH, Iyengar SK, Klein BE, et al., (2003): A whole-genome screen of a quantitative trait of age-related maculopathy in sibships from the Beaver Dam Eye study. Am J Hum Genet 72: 1412-1424. (Pubitemid 36628381)
29. Scholl HP, Fleckenstein M, Charbel Issa P, Keilhauer C, Holz FG, &, Weber BH, (2007): An update on the genetics of age-related macular degeneration. Mol Vis 13: 196-205. (Pubitemid 46232110)
30. Seddon JM, Ajani UA, Sperduto RD, et al., (1994): Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. JAMA 272: 1413-1420. (Pubitemid 24328383)
31. Seddon JM, Hankinson S, Speizer F, &, Willett WC, (1996): A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA 276: 1141-1146. (Pubitemid 26329740)
32. Seddon JM, Ajani UA, &, Mitchell BD, (1997): Familial aggregation of age-related maculopathy. Am J Ophthalmol 123: 199-206. (Pubitemid 27066775)
33. Seddon JM, Cote J, Davis N, &, Rosner B, (2003a): Progression of age-related macular degeneration: association with body mass index, waist circumference and waist-hip ratio. Arch Ophthalmol 121: 785-792. (Pubitemid 36676214)
34. Seddon JM, Santangelo SL, Book K, Chong S, &, Cote J, (2003b): A genomewide scan for age-related macular degenerations providences evidence for linkage to several chromosomal regions. Am J Hum Genet 73: 780-790. (Pubitemid 37271882)
35. Seddon JM, Gensler G, Milton R, Klein M, &, Rifai N, (2004): Association between C-reactive protein and age-related macular degeneration. JAMA 291: 704-710. (Pubitemid 38543790)
36. Seddon JM, George S, &, Rosner B, (2005): Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers. Arch Ophthalmol 123: 774-782. (Pubitemid 41056598)
37. Seitsonen S, Lemmelä S, Holopainen J, et al., (2006): Analysis of variants in the complement factor H, the elongation of very long chain fatty acids-like 4 and the hemicentin 1 genes of age-related macular degeneration in the Finnish population. Mol Vis 12: 796-801. (Pubitemid 44111652)
38. Seitsonen SP, Jarvela IE, Meri S, Tommila PV, Ranta PH, &, Immonen IJ, (2007): The effect of complement factor H Y402H polymorphism on the outcome of photodynamic therapy in age-related macular degeneration. Eur J Ophthalmol 17: 943-949. (Pubitemid 351262905)
39. Smith W, Assink J, Klein R, et al., (2001): Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology 108: 697-704. (Pubitemid 32238465)
40. StatSoft Inc. (1999): STATISTICA for windows [Computer program manual]. Tulsa, OK: StatSoft, Inc.
41. Tomany SC, Wang JJ, van Leeuwen R, et al., (2004): Risk factor for incident age-related macular degeneration. Pool findings from 3 continents. Ophthalmology 111: 1280-1287. (Pubitemid 38844822)
42. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (1999): Photodynamic therapy of subfoveal choroidal neovascularisation in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials-TAP report. Arch Ophthalmol 117: 1329-1345.
43. Wegscheider BJ, Weger M, Renner W, et al., (2007): Association of complement factor H Y402H gene polymorphism with different subtypes of exudative age-related macular degeneration. Ophthalmology 114: 738-742. (Pubitemid 46483679)
44. Zareparsi S, Branham KE, Li M, et al., (2005): Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration. Am J Hum Genet 77: 149-153. (Pubitemid 40848046)
45. Zipfel PF, (2001): Complement factor H: physiology and pathophysiology. Semin Thromb Hemost 27: 191-199. (Pubitemid 32550160)